Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Colorectal cancer rates are rising across nearly all age groups in the United States, reversing more than two decades of decline, according to a new study.

The disease is the second-leading cause of cancer-related deaths overall in the US and the leading cause among adults younger than 50. The latest findings, published in the journal NEJM Evidence, show that the increase now extends to older adults.

“This is the first time that we have seen an increase in the overall rate in more than 20 years,” said Caitlin Murphy, professor of pediatrics and public health sciences at the University of Chicago.

Rates Rise Across Age Groups

Also read: 3-Time Colon Cancer Survivor Reveals First Symptom She Noticed At 14

Researchers analyzed National Cancer Institute data from 2000 to 2023. The age-adjusted incidence rate fell from 55.2 per 100,000 people in 2000 to 36.7 in 2022, before rising to 38.3 in 2023.

The sharpest increase was seen among adults aged 45–49, with rates rising 12.76% annually from 2019 to 2023. Researchers attributed this partly to increased screening after US guidelines lowered the starting age from 50 to 45.

Currently US guidelines recommend that adults at average risk begin screening at 45 and continue through 75.

“That means that screening is doing as we intend it to do—it’s catching cancer earlier,” Murphy said.

However, screening alone does not explain the broader trend. Rates are also rising among adults aged 65–69 and have plateaued among those aged 70–74, despite about 80% of these groups being up to date with screening. The findings suggest unknown risk factors may be offsetting its benefits.

Birth Cohort Effect May Explain the Rise

Murphy described a possible “birth cohort effect,” in which people born in the 1960s and later face higher risks as they age.

“As people born around the same time move through time and age together, we’re going to see more colorectal cancers being diagnosed,” she said.

The researchers also examined whether COVID-19 disruptions contributed to the increase. However, the trend persisted after data from 2020 and 2021 were excluded, making the pandemic an unlikely explanation for the rise in 2023.

Read More: Aspirin & Colon Cancer: Lancet Study Explains Why It Could Help At An Earlier Stage But Not After Spread

Environmental Chemicals Likely Reason

Researchers have yet to identify the drivers, but environmental chemical exposures are one possible contributor.

The team plans to measure thousands of exposures in small blood samples, then use organoids—specialized models of colon tissue—to study the effects of chemicals warranting further investigation.

American Cancer Society statistics show that incidence among adults aged 20–49 increased by 3% annually from 2013 to 2022.

Sonia Kupfer, director of the Gastrointestinal Cancer Risk and Prevention Clinic at UChicago Medicine, said identifying the causes could help researchers pinpoint and potentially reduce risk factors.

Screening Remains Key

The American Cancer Society notes that colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancer impacts around 1.9 million people every year, noted the World Health Organization (WHO) as per its 2022 data.

It is a disease of large bowel and a type of cancer that originates from the rectum or colon. A person's colon, cecum, rectum and anus make up the large intestine.

The researchers called for continued monitoring as cancer registry data are updated annually. If the trend continues, rising diagnoses could increase demand for treatment and survivorship care.

Colonoscopy remains the gold standard, while blood-based and home-based stool tests offer alternatives. Adults younger than 45 who are not eligible for routine screening should watch for blood in the stool, changes in bowel habits and unexplained weight loss, and seek medical attention if these occur.

In January 2025, Los Angeles was ravaged by wildfires, which reportedly exposed an estimated 7 million people to lead concentrations more than 80 times higher than normal levels. The findings were published in Science Advances.

Researchers from the California Institute of Technology (Caltech) found that smoke from the Eaton Fire contained excessive concentrations of toxic metals and other chemicals than smoke from a wildfire that burned mainly vegetation. The findings highlight the health risks caused when fires spread through populated areas and burnt homes, vehicles and electronic equipment.

The lead exposure for an estimated 24-hour period across the Los Angeles metropolitan area was more than 80 times typical levels. The researchers also found that the fire plume contained 50 times more lead, three times more arsenic and seven times more chlorine and bromine than the smoke.

LA Wildfire Smoke Was Highly Toxic

Wildfire smoke is releases particulate matter from the burning of trees, grass and other vegetation. However, when fires spread deeper into cities, they can also burn building materials, paint, vehicles, plastics and electronic devices, releasing more toxic pollutants.

The Eaton Fire began on January 7, 2025, and ravaged communities in and around Altadena, California. As the fire burned homes and vehicles, concentrations of toxic metals in the atmosphere increased drastically.

The researchers compared the chemical composition of the Eaton Fire plume to measurements from the 2024 Airport Fire in Southern California, which predominantly burned vegetation. They found that the urban fire plume had a completely different chemical composition.

“Urban fire plumes are chemically distinct from those of wildfires. Now that we have these observational data about how they differ, we can go back and adjust our models to more accurately estimate how smoke might affect people,” said Haroula Baliaka, the study’s lead author, in a statement released by Caltech.

Also read: Recreational Drugs, Steroids & Birth Control: Expert Explains Why Strokes Are Arriving Decades Earlier

Health Risks Of Lead And Arsenic Exposure

Lead is a toxic metal that can damage the nervous system. In children, exposure can impair brain development and lower IQ. In adults, it can cause high blood pressure and other health problems.

Arsenic exposure is also connected to several cancers. Chlorine and bromine are halogens that can be released when certain materials burn.

However, scientists have not established the full health consequences of the short-term, high-concentration lead exposure estimated in the study. The findings establish that millions of people may have encountered elevated levels of toxic pollutants, but they do not show how many developed health problems as a result.

Urban Fire Smoke Needs Stricter Monitoring

Wildfire smoke threatens populated areas. Smoke can travel beyond the fire zone, exposing people who may not face an immediate risk from flames.

Researchers and outside experts have called for better monitoring of smoke composition, better public alerts and emergency responses that account for toxic pollutants as well as fire danger.

The study also points to a gap in current understanding of air quality models that are based on wildfire emissions. They may not be fully be able capture the chemical hazards from fires that burn buildings and vehicles.

“Smoke travels; it's not just about the burn area. What does a plume mean for people who are miles away from a fire but receive the smoke? We evacuate for fire, but we don't evacuate for smoke exposure,” Baliaka said according to CBS Los Angeles.

Tuberculosis (TB) remains the world’s leading cause of death from a single infectious agent. Treatment typically involves daily oral medicines that is taken for over weeks or months, making adherence a challenge for many patients.

To tackle this, the World Health Organization (WHO) has now released target regimen profiles for long-acting injectables (LAIs), which may soon replace pills with injections for TB preventive treatment and TB disease.

The new treatment regimen for tuberculosis with LAIs targets three or fewer injections in just four months.

These treatments are not yet commercially available for routine clinical use, but several candidates are entering clinical development.

“Long-acting injectables could make TB prevention and treatment much simpler for the people who need them. These profiles tell developers, early, what a new regimen must achieve to make that difference in practice, without trading away efficacy, safety or patient choice,” said Dr. Tereza Kasaeva, director of the WHO Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections.

What Are the WHO’s Targets for Long-Acting TB Injections?

Also read: 94% Of TB Patients Report Anxiety, 77% Depression: Study Highlights Mental Health Toll Of India's TB Burden

The WHO’s target regimen profiles (TRPs) define the minimum and optimal requirements for developing LAIs for TB prevention and treatment, guiding pharmaceutical companies, researchers, product developers, donors and TB-affected communities.

"The profile for TB preventive treatment aims for a complete course delivered through a single injection during one healthcare encounter. For TB disease, the target is a regimen lasting no more than four months, delivered in three or fewer dosing encounters," the WHO said.

Both profiles call for injections administered by trained health workers at the lowest feasible level of the health system. They also specify small injection volumes, no requirement for a cold chain, and efficacy and safety at least comparable to those of existing oral regimens. The profiles also address clinical trial design, scalability, equitable access and affordability.

How Could Long-Acting Injections Help People With TB?

Read More: ICMR's Advanced Blood Test to Predict Risk of TB 1.5 Years Before Symptoms Appear

LAIs are sustained-release medicines administered through intramuscular or subcutaneous injections. They have shown previously shown potential in managing conditions including HIV, schizophrenia, opioid dependence and contraception.

For HIV prevention, long-acting cabotegravir is administered every two months, while lenacapavir is administered twice yearly. WHO recommended lenacapavir for HIV prevention in 2025.

For people affected by TB, potential benefits include:

• Simpler adherence: Fewer doses could make it easier to complete treatment.
• Lower risk of drug resistance: Better adherence could reduce the risk of resistance developing during treatment.
• Reduced treatment burden: Fewer pills and healthcare visits could mean less time away from work and lower travel costs.
• Less stigma: Less frequent medication-taking and fewer healthcare visits could ease some of the burden associated with treatment.

However, LAIs address medication-taking frequency and adherence, not every challenge in TB care. Effective implementation would still require timely diagnosis, appropriate testing, management of comorbidities and drug interactions, contact investigation, and adequate healthcare resources.

Will Long-Acting TB Injections Be Affordable?

The WHO expects LAIs for TB prevention and treatment to enter the market at higher prices than existing oral formulations, based on anticipated development and production costs. International collaboration and support may be needed to ensure affordability, particularly during the initial rollout.

The WHO also emphasized that research into improved oral regimens should continue. Treatment programmes must preserve patient choice, allowing people who prefer oral medicines to continue using them.

Why Does This Matter for India?

According to the WHO’s Global Tuberculosis Report 2025, more than 10 million people developed TB worldwide in 2024, while more than 1.2 million died from the disease.

India bears the largest share of the global TB burden. Prolonged treatment, financial hardship, stigma and uneven access to drug-resistant TB care can make treatment more challenging.

If successfully developed and made accessible, long-acting injections could reduce some of the practical and economic barriers associated with TB treatment. Their impact will depend on safety, efficacy, affordability and equitable access.